Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959399 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01959399 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 24 participants.
The verdict
NCT01959399, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study will be to assess the effect of multiple-doses of ASP015K on the pharmacokinetics of rosuvastatin in healthy adult male and female subjects.
Interventions
- DRUG Rosuvastatin
- DRUG ASP015K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01959399
The ClinicalTrials.gov registry entry for NCT01959399 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT01959399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01959399 about?
NCT01959399 is a clinical study titled "Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin". The purpose of this study will be to assess the effect of multiple-doses of ASP015K on the pharmacokinetics of rosuvastatin in healthy adult male and female subjects.
What is the current status of trial NCT01959399?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-05. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01959399?
The interventions under investigation include: Rosuvastatin (DRUG), ASP015K (DRUG).
Who is sponsoring clinical trial NCT01959399?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.